 Home > Medical News > Latest Medical News > CS5001 clinical trial application by CStone Pharmaceuticals was approved by the U.S. FDA

CS5001 clinical trial application by CStone Pharmaceuticals was approved by the U.S. FDA

 Last Update: 2022-01-07
 Source: Internet
 Author: User

Tags

celexa drug interactions

latuda half life

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

ArticleMedicine Guanlan

On January 3, CStone Pharmaceuticals announced that its CS5001 clinical trial application (IND) has been approved by the US FDA

ROR1 is a typical tumor embryo protein, which is low or not expressed in adult tissues, but is highly expressed in a variety of tumors, including various types of leukemia, non-Hodgkin’s lymphoma, breast cancer, lung cancer and ovarian cancer Therefore, it is a very potential ADC target

CS5001 is an ADC targeting ROR1 with many differentiated features, including proprietary site-specific coupling, tumor-selective cleavable linker and prodrug technology

According to the press release, CS5001 has a unique design that uses tumor-specifically activated pyrrolobenzodiazepine (PBD) protoxin payload (Payload) and linker (linker)

Previously, CS5001 has been proven to have complete tumor suppressor effects in several preclinical cancer models, and exhibited good serum half-life and pharmacokinetic characteristics

Reference materials:

[1] CS5001 (ROR1 ADC) clinical trial application for CS5001 (ROR1 ADC), a potential global best-in-class drug, was approved by the U.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.